RE:RE:So 230 million shares, fully dilutedenriquesuave wrote: I think that if all warrants were excercised including new off would get company an extra $36 million. Enough to get all of PH2 and 2 PH1 trials for NSCLC and GBM and more. Total of $46 Million. It's a very reasonable move to get this going until major confirmation of initial PH2 data and hopefully a JV for GBM in the mean time which would add even more cash to the coffers. IMHO
Holy cow, almost $50 million??!!
That should last us several years, and get us through the Phase II NMIBC trial, and even through the Phase I GBM trial (even if we go it alone). In other words, this should be
the last PP until commercialization! Or am I missing something?
i always did my math for an eventual Big Pharma buyout based on 200 mil shares. So this is only 15% worse than I was already planning. And in return, we are the master of our own destiny. We didn't give away half the company on the cheap. We are not on the hook to have to share profits and revenue streams. We have complete freedom of action to entertain buyout offers down the road.
So if - and I say "if" - this is the last PP and gets us over the finish line, then all well and good. Now with funding out of the way (assuming the PP gets fully subscribed) let's get back to focusing on the fantastic science here. With no more funding distractions.
File the Phase II application with the FDA, and let's get the trial going! And get moving on the GBM Phase I as well!
GLTAL